Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma by Valletta, Daniela et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Regulation and function of the atypical cadherin FAT1 in hepatocellular
carcinoma
Valletta, Daniela; Czech, Barbara; Spruss, Thilo; Ikenberg, Kristian; Wild, Peter; Hartmann, Arndt;
Weiss, Thomas S; Oefner, Peter J; Müller, Martina; Bosserhoff, Anja-Katrin; Hellerbrand, Claus
Abstract: In human cancers, giant cadherin FAT1 may function both, as an oncogene and a tumor
suppressor. Here, we investigated the expression and function of FAT1 in hepatocellular carcinoma
(HCC). FAT1 expression was increased in human HCC cell lines and tissues compared with primary
human hepatocytes and non-tumorous liver tissue as assessed by quantitative PCR and western blot
analysis. Combined immunohistochemical and tissue microarray analysis showed a significant correlation
of FAT1 expression with tumor stage and proliferation. Suppression of FAT1 expression by short hairpin
RNA impaired proliferation and migration as well as apoptosis resistance of HCC cells in vitro. In nude
mice, tumors formed by FAT1-suppressed HCC cells showed a delayed onset and more apoptosis compared
with tumors of control cells. Both hepatocyte growth factor and hypoxia-mediated hypoxia-inducible
factor 1 alpha activation were identified as strong inducers of FAT1 in HCC. Moreover, demethylating
agents induced FAT1 expression in HCC cells. Hypoxia lead to reduced levels of the methyl group
donor S-adenosyl-L-methionine (SAM) and hypoxia-induced FAT1 expression was inhibited by SAM
supplementation in HCC cells. Together, these findings indicate that FAT1 expression in HCC is regulated
via promotor methylation. FAT1 appears as relevant mediator of hypoxia and growth receptor signaling
to critical tumorigenic pathways in HCC. This knowledge may facilitate the rational design of novel
therapeutics against this highly aggressive malignancy.
DOI: 10.1093/carcin/bgu054
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-97433
Accepted Version
Originally published at:
Valletta, Daniela; Czech, Barbara; Spruss, Thilo; Ikenberg, Kristian; Wild, Peter; Hartmann, Arndt;
Weiss, Thomas S; Oefner, Peter J; Müller, Martina; Bosserhoff, Anja-Katrin; Hellerbrand, Claus (2014).
Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis,
35(6):1407-1415. DOI: 10.1093/carcin/bgu054
For Peer Review
- REVISION - Valletta et al.: FAT1 in HCC  1 
Regulation and function of the atypical cadherin FAT1 in hepatocellular 
carcinoma 
 
Daniela Valletta 1, Barbara Czech 1, Thilo Spruss 2, Kristian Ikenberg 3, Peter Wild 3, 
Arndt Hartmann 4, Thomas S. Weiss 5, Peter J. Oefner 6, Martina Müller 1, Anja-Katrin 
Bosserhoff 7, and Claus Hellerbrand 1* 
 
1 Department of Internal Medicine I, University Hospital Regensburg, Germany 
2 Institute of Pharmacy, University of Regensburg, Regensburg, Germany 
3 Institute of Surgical Pathology, University Hospital Zurich, Switzerland 
4 Institute of Pathology, University Hospital Erlangen, Germany 
5 Department of Pediatrics and Juvenile Medicine, University Hospital Regensburg, 
Germany 
6 Institute of Functional Genomics, University of Regensburg, Germany 
7 Institute of Pathology, University of Regensburg, Germany 
 
*To whom correspondence should be addressed. University Hospital Regensburg, 
Department of Internal Medicine I, D-93053 Regensburg, Germany; Tel: +49-941-
944-7155; Fax: +49-941-944-7154; E-mail: claus.hellerbrand@ukr.de 
 
Page 1 of 36 Carcinogenesis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 at U
niversitaet Zuerich on July 18, 2014
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
For Peer Review
- REVISION - Valletta et al.: FAT1 in HCC  2 
ABSTRACT 
In human cancers, giant cadherin FAT1 may function both, as an oncogene and a 
tumor suppressor. Here, we investigated the expression and function of Fat1 in 
hepatocellular carcinoma (HCC). FAT1 expression was increased in human HCC cell 
lines and tissues compared to primary human hepatocytes and non-tumorous liver 
tissue as assessed by qPCR and Western Blot analysis. Combined 
immunohistochemical and tissue microarray analysis showed a significant correlation 
of FAT1 expression with tumor stage and proliferation. Suppression of FAT1 
expression by shRNA impaired proliferation and migration as well as apoptosis 
resistance of HCC cells in vitro. In nude mice, tumors formed by FAT1-suppressed 
HCC cells showed a delayed onset and more apoptosis compared to tumors of 
control cells. Both hepatocyte growth factor and hypoxia-mediated HIF1alpha 
activation were identified as strong inducers of FAT1 in HCC. Moreover, 
demethylating agents induced FAT1 expression in HCC cells. Hypoxia lead to 
reduced levels of the methyl group donor S-adenosylmethionine (SAM) and hypoxia-
induced FAT1 expression was inhibited by SAM supplementation in HCC cells. 
Together, these findings indicate that FAT1 expression in HCC is regulated via 
promotor methylation. Conclusion: FAT1 appears as relevant mediator of hypoxia 
and growth receptor signaling to critical tumorigenic pathways in HCC. This 
knowledge may facilitate the rational design of novel therapeutics against this highly 
aggressive malignancy. 
 
SUMMARY 
Giant cadherin FAT1 is increased in hepatocellular carcinoma (HCC) and is a 
protumorigenic factors in HCC-cells.
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INTRODUCTION 
Cadherins are major contributors to cell-cell adhesion in epithelial tissues and play a 
critical role in morphogenetic and differentiation processes during development, and 
in maintaining integrity and homeostasis in adult tissues [1]. Several cadherins have 
been identified as potential tumor suppressors or oncogenic proteins depending on 
the type of cadherin and the type of cancer [2]. The cadherin subfamily FAT is 
characterized by large extracellular domains containing 34 cadherin motifs, making it 
the largest of all cadherin molecules [3]. The first identified member of this family, 
Drosophila Fat, has been shown to be involved in cell proliferation and survival as 
well as cellular polarity [4]. FAT1 was identified as the first Fat-like protein in 
vertebrates [5]. Mice lacking FAT1 exhibit perinatal lethality with defects in kidney 
and brain [6]. Transcript variants derived from alternative splicing exist, but their 
differential function just begins to be elucidated [7]. Moreover, FAT1's mechanisms of 
action in normal and diseased tissues are incompletely understood [3;8]. In cancer 
FAT1 appears to act as tumor suppressive or oncogenic in a context-dependent 
manner [8]. Frequent loss of heterozygosity of FAT1 has been described in oral 
squamous cell carcinomas and astrocytic tumors [9;10]. In cholangiocarcinoma 
immunohistochemistry demonstrated reduced FAT1 expression at the normal 
membranous location [11] and FAT1 is preferentially downregulated in invasive 
breast cancer [12]. In contrast, FAT1 is upregulated in leukemia and prognosis of 
precursor B-cell acute lymphoblastic leukemia patients with FAT1 upregulation is 
poor [13]. Functional in vitro studies revealed that FAT1 acts as a regulator of 
oncogenic pathways in glioma cell lines [14].  
Here, we aimed to assess the expression and function of FAT1 in hepatocellular 
carcinoma (HCC), which is the fifth most common cancer worldwide and the third 
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most common cause of cancer mortality [15]. HCC is strongly associated with liver 
fibrosis, with 90% of HCC cases arising in cirrhotic livers [16]. Recently, we have 
shown increased FAT1 expression during liver fibrogenesis, and identified activated 
hepatic stellate cells (HSCs) as the cellular source of increased FAT1 expression in 
diseased livers [17]. In the present study, we describe a novel mechanism by which 
activated HSCs induce FAT1 expression in HCC cells and identify FAT1 as tumor 
promoter in this highly aggressive hepatic cancer. 
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MATERIALS AND METHODS 
Cells and cell culture 
The HCC cell lines HepG2 (ATCC HB-8065), PLC (ATCC CRL-8024) and Hep3B 
(ATCC HB-8064) were cultured as described [18]. Primary human hepatocytes 
(PHH) and hepatic stellate cells (HSCs) were isolated and cultured as described [18-
20]. In vitro activation of HSCs was achieved by cell culture on uncoated tissue 
culture dishes [20]. Collection of conditioned medium (CM) from activated HSCs and 
control medium was done as described [18]. For individual experiments, CM was 
preincubated with anti-human hepatocyte growth factor (HGF) or isotope-control 
antibodies (100 µg/mL; all from R&D Systems; Wiesbaden, Germany). Recombinant 
HGF was purchased from R&D Systems. 
Hypoxia was induced by exposure to 1% O2 or incubation with 2,2-dipyridyl (DP) 
(100 µmol/L; Sigma-Aldrich, Deisenhofen, Germany) for the indicated periods of time. 
For pharmaceutical inhibition of hypoxia-inducible factor (HIF)-1 activity, cells were 
incubated with 10 nmol/L of echinomycin (Alexis Biochemicals, Lörrach, Germany). 
Protein synthesis was inhibited by cycloheximide (CHx) and for demethylation cells 
were stimulated with either 5-aza-2‘deoxycytidine (Aza), adenosine-2′,3′-dialdehyde 
(Adox) or S-adenosyl-L-methionine (SAM) (all from Sigma-Aldrich). 
Human tissues and HCC tissue microarray 
Paired HCC and non-neoplastic liver tissues were obtained from HCC patients 
undergoing surgical resection. Tissue samples were immediately snap-frozen and 
stored at -80°C until analysis. A tissue microarray (TMA) of paraffin-embedded HCC 
samples was constructed as described [18;21-23]. Clinicopathological patient 
characteristics are summarized in Table 1.  
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Tissue samples from liver resections for cell isolation and expression analyses were 
obtained from patients undergoing partial hepatectomy. Experimental procedures 
were performed according to the guidelines of the charitable state controlled 
foundation HTCR (Human Tissue and Cell Research), with the informed patient's 
written consent approved by the local ethical committee of the University of 
Regensburg [24]. All experiments involving human tissues and cells have been 
carried out in accordance with The Code of Ethics of the World Medical Association 
(Declaration of Helsinki). 
Transfection of HCC cell lines 
Applying the Lipofectamine plus method (Invitrogen, Carlsbad, USA) cells were 
transfected with a dominant-negative HIF1α construct (dnHIF1α) [25]. FAT1-
suppressed cell clones were established by stable transfection of PLC cells with a 
FAT1 shRNA plasmid. The FAT1 shRNA plasmid was prepared as previously shown 
[26]. Plasmids were cotransfected with pcDNA3 (Invitrogen), containing the 
selectable marker for neomycin resistance. Controls received pcDNA3 alone. One 
day after transfection, cells were placed in selection medium containing 200 µg/mL 
G418 (Sigma). After 25 days of selection, individual G418-resistant colonies were 
subcloned. 
 
AP-1 reporter gene assay.  
Cells were transfected with a pAP-1 luc plasmid (Stratagene, La Jolla, USA) using 
Lipofectamine Plus reagent (Invitrogen, Karlsruhe, Germany)  as described [17]. For 
normalization of transfection efficiency, cells were contransfected with pRL-TK 
plasmid resulting in a renilla luciferase acitivity (Promega, Mannheim, Germany), and 
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after 24 h cells were lysed and the luciferase activities were measured as described 
[17]. 
Expression analysis 
Isolation of total cellular RNA from cultured cells and tissues and reverse 
transcription were performed as described previously. Quantitative real time-PCR 
was performed on a LightCycler (Roche, Mannheim, Germany) using the following 
sets of primers: AT1 (for: 5’-GTG TTT GTT CTC TGC CGT AAG-3’; rev: 5’-TAG 
GCT TCT GGA TGG AGT CG-3’), E-CAD (for: 5’-ATC CTC CGA TCT TCA ATC 
CCA CCA C-3’; rev: 5’-GTA CCA CAT TCG TCA CTG CTA CGT G-3’), MAT2A (for: 
5’-CCA CGA GGC GTT CAT CGA GG-3’; rev: 5’-AAG TCT TGT AGT CAA AAC CT-
3’). VEGF, SNAIL, MAZ and PDCD4 mRNA expression analysis were performed 
using QuantiTect Primer Assay according to the manufacturer’s instructions (Qiagen, 
Hilden, Germany). 
Protein analysis  
Protein extraction and Western Blotting were performed as described [18] using the 
following antibodies: anti-FAT1 (1:1,000, Atlas Antibodies AB, Stockholm, Sweden), 
anti-HIF1α (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-β-
actin (1:20,000, Sigma).  
For immunohistochemistry, HE-staining, and TUNEL-staining, standard 5-µm 
sections of formalin-ﬁxed and parafﬁn-embedded tissue blocks were used.  
Immunohistochemical staining was performed using the following antibodies: anti-
FAT1 (1:50, Atlas Antibodies AB), Ki67 (MIB1, 1:50, Abcam, Cambridge, UK), 
Caspase 3 (1:150, Epitomics, Burlingame, CA, USA) and anti-c-Jun (1:100, #9165, 
Cell Signaling Technology), as described [28]. TUNEL staining was performed as 
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described [21]. 
For analysis of the tissue microarray, positivity for FAT1 was defined as detectable 
membranous staining, whereas cases designated as FAT1 negative were devoid of 
FAT1 staining. 
S-Adenosyl-L-methionine (SAM) extraction and analysis 
For analysis of S-adenosyl-L-methionine (SAM) in cell culture medium, cells were 
cultured in serum free medium for 24 h. Subsequently, medium was collected, 
centrifuged, and the supernatant was snap-frozen and stored at -80°C. SAM analysis 
was performed with liquid chromatography-electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS) as described [29]. 
Analysis of proliferation, migration and resistance against sorafenib treatment 
Cell proliferation was measured using the XTT assay (Roche) as described [22]. Cell 
migration was quantified using the xCELLigence system according to the instructions 
of the supplier (Roche Applied Science).  
To analyze the resistance against sorafenib treatment, cells were incubated with 
different doses of sorafenib (3 µM, 10 µM, 30 µM) or vehicle (DMSO) for 48h followed 
by analysis of XTT activity. 
Analysis of apoptosis 
For detection of apoptosis, cells were stained simultaneously with FITC-conjugated 
Annexin V and propidium iodide (both from Pharmingen, Germany) and analyzed by 
flow cytometry [20]. Further, the Caspase-Glo 3/7 Assay (Promega, Madison, WI, 
USA) was used to analyze caspase-3/7 activity [30]. 
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Tumor cell inoculation and measurement of tumor growth in NMRI (nu/nu) mice 
A model of inoculation of tumor cells into NMRI (nu/nu) mice to monitor tumor growth 
in vivo was performed as described [21;22] following the institutional (University 
Regensburg) and national guidelines for the care and use of animals. For ethical 
reasons, mice were sacrificed upon observation of the first signs of tumor ulceration. 
Tumors were excised, snap frozen and stored in liquid nitrogen for subsequent 
analysis.  
 
Statistical analysis 
Results are expressed as mean ± standard error (range) or percent. Comparison 
between groups was made using the Student's unpaired t-test. A p value <0.05 was 
considered statistically significant. Contingency table analysis and the two-sided 
Fisher’s exact test were used to study the statistical association between 
clinicopathological and immunohistochemical variables. All calculations were 
performed by using the GraphPad Prism Software (GraphPad Software, Inc., San 
Diego, USA) or SPSS (SPSS, Chicago, IL, USA).  
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RESULTS 
FAT1 expression in HCC 
Initially, we analyzed FAT1 mRNA expression in three different HCC cell lines 
(HepG2, PLC, and Hep3B) and primary human hepatocytes (PHH) by quantitative 
real-time PCR and Western Blot analysis. In all three HCC cell lines FAT1 mRNA and 
protein expression were significantly increased compared to PHHs (Figure 1A,B). 
Comparison of human HCC tissue and corresponding non-tumorous liver tissue of 14 
patients confirmed a strong upregulation of FAT1 mRNA in cancerous tissue (Figure 
1C). 
To evaluate the functional effects of FAT1 upregulation in HCC in vivo, we analyzed 
FAT1 protein expression in a series of 112 human HCC tissues, applying 
immunohistochemistry and tissue microarray (TMA) technology. Membranous FAT1 
staining intensity varied significantly among individual patients. For descriptive data 
analysis, HCC were scored as exhibiting either strong or weak immunosignal 
(representative examples are depicted in Figure 1D), and immunohistochemical 
results were correlated with clinicopathological characteristics (Table 1). Strong 
membranous FAT1 staining was significantly associated with higher tumor stage 
(p=0.042) and proliferation rate (MiB index; p=0.040), respectively. No correlation 
was found between FAT1 expression and tumor grading and tumor size or patients' 
age and sex.  
Inhibition of FAT1 expression in HCC cells 
To gain insight into the functional role of increased FAT1 in HCC, we inhibited FAT1 
expression in the HCC cell line PLC by stable transfection with a shRNA expression 
vector containing the sequence of FAT1 siRNA (FAT1 shRNA#1, FAT1 shRNA#2). 
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PLC cells transfected with the empty vector served as control. Quantitative RT-PCR 
and Western Blot analysis revealed a strong downregulation of FAT1 expression in 
FAT1 shRNA compared to control cell clones (Figure 2A). FAT1-suppressed HCC 
cells showed normal histological morphology (Figure 2B), and also the expression of 
E-Cadherin (E-Cad) and Snail, two markers of epithelial-mesenchymal transition, did 
not differ significantly compared to control cells (Supplementary Figure 1).  
To characterize the role of FAT1 in HCC cells, we performed functional in vitro 
assays with FAT1-suppressed cells in comparison to control cells. HCC cells with 
suppressed FAT1 expression grew significantly slower (Figure 2C). Migration assays 
demonstrated that suppression of FAT1 inhibited the migratory potential of HCC cells 
(Figure 2D). Moreover, serum starvation induced significantly higher caspase-3/7 
activation (Figure 2E) and a higher apoptosis rate in HCC cells with suppressed 
FAT1 expression compared to control cells (Figure 2F). We also analyzed the 
resistance of FAT1 suppressed and control cells against sorafenib treatment in vitro 
but did not observe significant differences (Figure 2G). 
In search for the underlying mechanism of FAT1 on proliferation, migration and 
apoptosis resistance in HCC cells, we analyzed expression of tumor-suppressor 
gene programmed cell death 4 (PDCD4) because a recent study by Dikshit et al. 
identified FAT1 as inhibitor of this tumor-suppressor gene in glioblastoma multiforme 
[14]. Also in HCC PDCD4 was identified as tumor-suppressor gene inducing 
apoptosis and inhibiting their metastatic potential [31;32]. However, PDCD4 
expression levels did not differ significantly between FAT1 suppressed and control 
cells (Supplementary Figure 2A). Moreover, Dikshit and collegues discoverd that 
FAT1 inhibited c-Jun phosphorylation and herewith led to the attenuation of activator 
protein-1 (AP-1) in glioblastoma. AP-1 is a critical regulator of tumorigenicity of HCC 
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cells [33;34] but reporter gene analysis showed similar activity in HCC cells with and 
without FAT1 suppression (Supplementary Figure 2B).  
 
Tumorigenicity of FAT1-suppressed HCC cells in vivo 
To test the effect of FAT1 on tumor growth in vivo, HCC cells stably suppressing 
FAT1 and control cells were injected subcutaneously into nude mice. Tumors derived 
from FAT1-suppressing HCC cell clones showed delayed tumor onset compared to 
tumors derived from mock-transfected control cells (Figure 3A). Expression analysis 
revealed preservation of FAT1 mRNA suppression in tumors (Figure 3B). Terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL staining) showed only 
few apoptotic cells in control-transfected HCC derived tumors, whereas the FAT1-
suppressing tumors displayed large apoptotic areas (Figure 3C).  
 
Regulation of FAT1 expression in HCC cells 
Activated hepatic stellate cells (HSCs) form and transduce the HCC stroma [35]. 
Previously, we have shown that HSCs secrete factors by which they promote growth 
and migration of HCC cells in vitro [36]. This prompted us to examine the effect of 
conditioned media (CM) from activated HSCs on FAT1 mRNA expression in HCC 
cells. Quantitative RT-PCR showed increased FAT1 mRNA expression in HCC cells 
after incubation with CM from HSCs (Figure 4A). In search for the factors in CM of 
HSCs responsible for FAT1 upregulation in HCC cells we focused on hepatocyte 
growth factor (HGF), which is known to promote hepatocancerogenesis . 
Stimulation of HCC cells with HGF (50 ng/mL) induced a significant upregulation of 
FAT1 mRNA and protein expression (Figure 4B). Preincubation of CM from activated 
HSCs with anti-HGF antibodies completely abrogated the stimulating effect on FAT1 
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(Figure 4C). Together, these data indicate that activated HSCs induce FAT1 in HCC 
cells via HGF secretion.  
To further elucidate the HGF-induced transcriptional regulation of FAT1 we focused 
on hypoxia inducible factor 1 alpha (HIF1α), because it has been shown that HGF 
enhances the activity of this transcription factor in HCC cells [37]. Further, HIF1α 
plays a critical role in HCC development and progression [38]. HGF-induced FAT1 
expression was completely inhibited by echinomycin, a pharmaceutical inhibitor of 
HIF1α activity (Figure 4D). HIF1α is also an important mediator of hypoxic adaption 
of tumor cells [39], and accordingly, induction of hypoxia by incubation with the 
chemical inducer Dipyridyl (DP) caused a significant upregulation of FAT1 (Figure 
4E,F). Western Blot analysis demonstrated stabilization of HIF1α in DP-treated cells 
(Figure 4F). FAT1 upregulation under DP-induced hypoxia was strongly repressed 
by echinomycin (Figure 4G). In line with this finding, transient transfection with a 
dominant-negative variant of HIF1α [40] led to diminished DP-induced FAT1 
expression (Figure 4H). Together, these data indicate HIF1α as critical regulator of 
HGF- and hypoxia-induced FAT1 expression in HCC cells. 
Mechanisms of FAT1 regulation in HCC 
However, in silico analysis of the FAT1 promoter did not show an HIF1 binding site 
(Tess (http://www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=WELCOME) and Genomatix 
software; data not shown). Furthermore, costimulation with cycloheximide, an 
inhibitor of protein synthesis, abolished HGF- and hypoxia-induced upregulation of 
FAT1 mRNA expression in HCC cells (Figure 5A and Supplementary Figure 2). 
These data indicated that hypoxia and HIF1α, respectively, did not directly induce 
FAT1 expression at the transcriptional level. Still, hypoxia can cause epigenetic 
modifications as demethylation [41], and it has been shown that the methylation 
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status of the FAT1 CpG island in squamous cell carcinomas correlated negatively 
with its expression [10]. Here, we found that incubation with 5-aza-2‘deoxycytidine 
(Aza) and adenosine-2′,3′-dialdehyde (Adox) both inhibitors of DNA methylation, 
caused a dose-dependent upregulation of FAT1 expression in HCC cells (Figure 
5B). Most recently, it has been shown that hypoxia-induced DNA demethylation in 
HCC is caused through activation of HIF1α and transcriptional upregulation of 
methionine adenosyltransferase II, alpha (MAT2A) [42]. MAT is the critical enzyme 
for the reaction of methionine and ATP to SAM. There are two genes (MAT1A, 
MAT2A) for two homologous catalytic MAT subunits (MATI, MATII). While MAT1A is 
mainly expressed in healthy liver, a switch from MAT1A to MAT2A takes place during 
the progression of HCC [43]. This leads to reduced SAM levels due to the lower 
enzymatic activity of MATII compared to MATI [44]. Also in the present study we 
observed reduced SAM-levels in the supernatant of HCC cells after chemical 
induction of hypoxia (Figure 5C). Replenishment of SAM in culture medium of HCC 
cells dose-dependently inhibited hypoxia-induced FAT1 expression (Figure 5D). 
These findings indicate that hypoxia-induced FAT1 expression in HCC cells is 
mediated via MAT2A-mediated SAM depletion and subsequent demethylation of the 
FAT1 promotor. 
To verify these findings in vivo we assessed FAT1 and vascular endothelial growth 
factor (VEGF) expression in 25 human HCC specimens by qRT-PCR. VEGF is highly 
regulated by HIF1α in HCC [45], and notably, we found a significant correlation 
between VEGF and FAT1 expression in HCC tissues (Figure 5E). Furthermore, 
FAT1 and MAT2A expression showed a significant correlation in HCC tissues 
(Figure 5F). Together, these data suggest that also in vivo hypoxia is a critical 
regulator of FAT1 expression in HCC. This effect seems to be at least in part 
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mediated via enhanced MAT2A expression and subsequent depletion of SAM levels 
leading to demethylation of the FAT1 promoter. 
In search for the molecular mechanisms responsible for the significantly enhanced 
basal FAT1 expression levels in HCC cells compared to hepatocytes, we focused on 
Myc-associated zinc finger protein (MAZ) because in silico analysis (Genomatix 
software) revealed a MAZ binding site located 242 bp upstream of the transcriptional 
start site of the human FAT1 gene. Furthermore, we have previously shown that MAZ 
expression in HCC cells is markedly enhanced compared to PHHs [18]. Transient 
transfection with two different MAZ siRNAs significantly inhibited MAZ mRNA 
expression in Hep3B cells compared to HCC cells transfected with control siRNA (ctrl 
siRNA) and non-transfected control cells (ctrl) (Figure 5G). Notably, MAZ 
suppression caused a significant but not complete downregulation of FAT1 
expression in HCC cells (Figure 5H). 
In summary, these data indicate that constitutively high FAT1 mRNA expression in 
HCC cells under normoxic conditions is at least in part dependent on the transcription 
factor MAZ. FAT1 mRNA expression is further increased via HGF secreted HGF or 
hypoxia induced HIF-1 activation in HCC. 
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DISCUSSION 
The giant cadherin FAT1 is one of four vertebrate orthologues of the Drosophila 
tumor suppressor fat. The specific function of FAT1 in cancer development and 
progression is still under investigation. There are contrasting studies about the role of 
FAT1 in human cancers, pointing towards a dual role of FAT1 as both an oncogene 
as well as a tumor suppressor [9-13;46]. Here, we found increased FAT1 expression 
in HCC cells and tissues compared to primary human hepatocytes and non-tumorous 
liver tissue. Furthermore, FAT1 expression correlated with higher tumor stage and 
mitotic activity in human HCCs. These findings indicated that FAT1 acts oncogenic in 
HCC, and in functional studies we identified a protumorigenic effect of FAT1 in HCC 
cells. We observed reduced migratory potential in HCC cells upon FAT1 suppression 
in concordance with studies on squamous cell carcinoma and glioma cells [9-14]. In 
breast cancer, FAT1 seems to inhibit progression to an invasive phenotype [47] . In 
cholangiocarcinoma, FAT1 expression showed an inverse correlation with the 
proliferation index and loss of membranous FAT1 localization correlated with more 
aggressive tumor growth [11] In non-malignant vascular smooth muscle cells FAT1 
knockdown lead to decreased migratory activity but surprisingly and in contrast to our 
findings in HCC cells enhanced proliferation [48]. In addition to its varying effects on 
proliferation and migration in different cell types, FAT1 is engaged in several other 
biological functions such as polarity and adhesion or as a regulator of inflammatory 
pathways in cancer cells [49]. However, available literature has not yet functionally 
linked FAT1 to apoptosis. Here, we demonstrate that FAT1 downregulation impairs 
the resistance of HCC cells against induced apoptosis in vitro. Also in vivo tumors 
derived from HCC cells with repressed FAT1 expression revealed significantly more 
apoptosis than tumors derived from control HCC cells. In summary, our data indicate 
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FAT1 as tumor promotor in HCC. Differently than observed in glioblastoma 
multiforme [14] , we did not observe that FAT1 affected PDCD4 expression levels or 
AP-1 activity in HCC cells. Currently, we can only speculate on the pro-tumorigenic 
molecular mechanisms set in motion by FAT1 expression in HCC. A most recent 
review by Sadeqzadeh and colleagues [50] highlights that we are just beginning to 
understand the molecular interactions of FAT1, which vary in different tissues and in 
health and disease. Future studies have to identify the mechanism by which FAT1 
exhibits protumorigenic effects in HCC. 
In this study we focused on the molecular mechanism responsible for the 
transcriptional upregulation of FAT1 in HCC. Here, we investigated effects mediated 
by activated hepatic stellate cells (HSCs) because these cells form and infiltrate the 
HCC stroma and affect HCC development and progression [16;36;46;51;52]. 
Furthermore, we recently identified activated HSCs as the cellular source of 
increased FAT1 expression in liver fibrosis and demonstrated that FAT1 is a 
profibrogenic factor in these cells [17]. Due to these profibrogenic effects in HSCs 
and due to the here newly described tumorigenic effects, FAT1 might constitute an 
excellent therapeutic target in chronic liver disease. Moreover, we found that 
activated HSCs induce FAT1 expression in HCC cells underscoring the critical role of 
activated HSCs in hepatocancerogenesis [16]. 
Interestingly, activated HSCs induce FAT1 in HCC cells via secreted HGF. This 
multifunctional growth factor and its receptor and its high-affinity tyrosine kinase 
receptor c-MET are critical regulators of HCC development and progression [53]. We 
found that the HGF effect on FAT1 activation is mediated via increased activation of 
HIF1α, which plays a critical role in hepatocancerogenesis [38] In addition to HGF, 
hypoxia typically stabilizes HIF1α and herewith leads to an activation of this pathway. 
Hypoxic conditions frequently occur in tumorous tissue and are another critical 
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promoter of HCC progression [39]. Interestingly, we found that HIF1α effects on 
FAT1 expression in HCC cells were not mediated directly at the transcriptional level 
but via reduction of the levels of the methyl donor S-adenosyl-L-methionine (SAM). 
Liu and colleagues identified HIF1α-mediated upregulation of MAT2A as a novel 
mechanism, by which hypoxia induces DNA demethylation [42]. We confirmed a 
significant correlation between FAT1 and MAT2A in HCC tissues. Together, these 
findings lead to the following model of FAT1 regulation in HCC 
cells (Supplementary Figure 4): HGF-induced and hypoxia mediated HIF1α 
activation enhances MAT2A expression and herewith MATII activity. As a result MATI 
activity is reduced, leading to lower levels of the methyl donor SAM. Lower SAM 
levels cause reduced methylation of the FAT1 promoter and thereby higher FAT1 
expression.  
A previous study described the regulatory role of SAM in HGF-mediated hepatocytes 
proliferation through a mechanism that implicated the activation of the non-canonical 
LKB1/AMPK/eNOS cascade and the function of human antigen R (HuR), which 
stabilizes MAT2A mRNA [54]. In HCC cells we identified a different regulatory 
pathway by which HGF - and also hypoxia - affected SAM levels, and herewith, FAT1 
promoter methylation. Thus, this study identifies an example how signaling pathways 
propagated from the cell surface through transmembrane receptors to intracellular 
regulatory mechanisms are critical for normal as well as aberrant cellular functions. 
This knowledge may provide the basis for the rational design of novel therapeutics to 
inhibit HCC development and progression. 
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Table 1: FAT1 immunoreactivity (IR) in HCC-tissue of 112 patients in relation to 
clinicopathological characteristics and proliferation rate. 
 
Variable         FAT1 IR FAT1 IR 
P* 
  Categorization n %   weak strong 
         
Clinico-pathological characteristics     
         
Age at diagnosis       
  <60 years 40 35.7  13 27 1.000 
  ≥60 years 72 64.3  23 49  
        
Gender        
  female 17 15.2  3 14 0.259 
  male 95 84.8  33 62  
       
Tumour stage       
  pT1 42 37.5  17 25 0.042 
  pT2 27 24.1  12 15  
  pT3 38 33.9  6 32  
  pT4 3 2.7  1 2  
  nd 2 1.8  0 2  
       
Histological grade       
  G1 42 37.5  14 28 1.000 
  G2 59 52.7  19 40  
  G3 11 9.8  3 8  
       
Tumor size       
  ≤ 5 cm 60 53.6  19 41 0.921 
  > 5 cm 36 32.1  11 25  
  nd 16 14.3  6 10  
        
Proliferation rate (MIB1-Index)      
  ≤ 5% 46 41.1  20 26 0.040 
  > 5% 66 58.9  16 50  
          
* Fisher's exact test (2-sided); bold face representing P-values <0.05. 
(nd: no data available; IR: immunoreactivity) 
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FIGURE LEGENDS 
Fig. 1: FAT1 expression in HCC 
(A) mRNA and (B) protein expression of FAT1 in HCC cell lines (HepG2, PLC, and 
Hep3B) and primary human hepatocytes (PHH). (C) FAT1 mRNA expression in 
tumor tissue of 14 HCC patients (T) and in corresponding non-neoplastic liver (NT). 
(D) Examples of weak (I) and strong (II) immunohistochemical FAT1 staining of 
human HCC tissues. (*: p < 0.05 compared to PHH or NT). 
 
Fig. 2: Inhibition of FAT1 expression in HCC cells 
(A) FAT1 mRNA and protein expression in HCC cell clones stably transfected with 
FAT1 shRNA (FAT1 shRNA#1; FAT1 shRNA#2) or control shRNA (ctrl). (*: p < 0.05 
compared to ctrl). (B) Morphology of FAT1-suppressed and control cells. (C) 
Doubling time and (D) migration of FAT1-suppressed and control cells (*: p < 0.05 
compared to ctrl). (E) Analysis of caspase 3/7 activity in FAT1-suppressed and 
control cells after serum deprivation. (*: p < 0.05 compared to ctrl). (F) Assessment of 
apoptosis by flow cytometry applying annexin V and propidium iodide (PI) staining. 
Depicted is the mean-percentage of total apoptotic cells from 3 independent 
experiments. (*: p < 0.05 compared to ctrl). (G) Analysis of XTT activity in FAT1-
suppressed and control cells after incubation with sorafenib (3 µM, 10 µM, 30 µM) in 
relation to control cells without sorafenib treatment. (*: p < 0.05 compared to cells 
without sorafenib treatment). 
 
Fig. 3: Tumorigenicity of FAT1-suppressed HCC cells in vivo 
(A) Onset of tumors derived from FAT1-suppressed or control cells implanted in nude 
mice. (B) FAT1 mRNA expression in tumors derived from FAT1-suppressed or 
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control cells. (C) Analysis for apoptotic cells in tumor tissue using TUNEL staining 
(green) and DAPI staining for nuclei (blue). (*: p < 0.05 compared to ctrl). 
 
Fig. 4: Regulation of FAT1 in HCC cells 
(A) Analysis of FAT1 mRNA expression in HCC cells after incubation with control 
medium (ctrl) and conditioned medium (CM) of HSCs. (B) Analysis of FAT1 mRNA 
and protein expression after incubation with HGF (50 ng/mL). (C) Effect of anti-HGF 
antibodies on FAT1 mRNA expression in the presence of CM. CM was preincubated 
with anti-HGF antibodies or isotype matched control antibodies (ctrl IgG) before 
addition to HCC cells. (*: p < 0.05 compared to ctrl; #: p < 0.05 compared to CM).  
(D) FAT1 mRNA expression in HGF-stimulated cells with or without inhibiting HIF1α 
with Echinomycin (Ech). (E) Analysis of FAT1 mRNA expression in HCC cells after 
pharmaceutical induction of hypoxia by dipyridyl (DP). (F) FAT1 and HIF1α protein 
expression after chemical induction of hypoxia by DP. (G) FAT1 mRNA expression 
with or without pharmaceutical induction of hypoxia and HIF1α inhibition with Ech by 
quantitative PCR. (H) Analysis of FAT1 mRNA after transfection of HCC cells with a 
dominant-negative variant of HIF1α (dnHIF1α) with or without stimulation with DP. 
(*: p < 0.05 compared to DP). 
 
Fig. 5: Mechanisms of FAT1 regulation in HCC  
(A) FAT1 mRNA expression in DP stimulated cells with or without blocking protein 
synthesis by cycloheximide (CHx). (#: p < 0.05). (B) Analysis of FAT1 mRNA 
expression in HCC cells after treatment with different doses of 5-aza-2‘deoxycytidine 
(Aza) and adenosine-2′,3′-dialdehyde (Adox) for 48h. (*: p < 0.05). (C) SAM level 
after induction of hypoxia with DP analyzed by liquid chromatography-electrospray 
ionization-tandem mass spectrometry. (*: p < 0.05). 
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 (D) FAT1 mRNA expression in HCC cells stimulated with different doses of SAM and 
subsequent induction of hypoxia with DP for 48h. (*: p < 0.05 compared to ctrl; 
#: p < 0.05 compared to DP). (E) Correlation of FAT1 with VEGF and (F) MAT2A 
mRNA expression in HCC tissue (n=24). (G) Analysis of MAZ and (H) FAT1 mRNA 
expression in HCC cells transiently transfected with two different MAZ siRNAs 
(siRNA#1 and siRNA#2) or control siRNA (ctrl siRNA) and non-transfected control 
cells (ctrl). (*: p < 0.05 compared to ctrl siRNA). 
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